New Drug Application for RiVive™ Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA
US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals
OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose
Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses